What is the primary difference between pancreatic islet cell transplantation and whole pancreas transplantation for patients with Type 1 diabetes?

The fundamental difference between pancreatic islet cell transplantation and whole pancreas transplantation lies in the nature and scope of the surgical procedure. Both aim to provide the patient with healthy, insulin-producing beta cells, but the implementation method differs significantly. A whole pancreas transplant is a major and complex surgery involving the transplantation of an entire organ, whereas islet cell transplantation focuses only on injecting specific cells into the liver [1].

Differences in Surgical Procedure

Whole pancreas transplantation relies on replacing a damaged pancreas with a healthy one from a deceased donor; this is a major surgical procedure that carries a high risk of complications. In contrast, islet cell transplantation is a less invasive procedure. Islet cells, which contain the insulin-secreting beta cells, are isolated and purified from the donor pancreas in a laboratory. A physician then injects these cells through a thin tube (catheter) guided into the portal vein of the liver using imaging and ultrasound. This procedure may require more than one injection to ensure there is a sufficient number of functioning cells in the patient's body [1], [2].

Risks and Side Effects

Despite the difference in technique, both procedures share the requirement that the patient must take immunosuppressive medications for life. These drugs are necessary to prevent the immune system from attacking the transplanted cells or organ, but they carry significant health risks. Common side effects of these medications include increased susceptibility to infection, digestive disorders such as nausea, vomiting, and diarrhea, as well as headaches, tremors, high blood pressure, or elevated levels of cholesterol and triglycerides, and potential adverse effects on kidney function [1].

Who Are the Candidates and What Are the Expectations?

Islet cell transplantation is not available for every patient with Type 1 diabetes; it is reserved for specific groups of adults who have severe difficulty controlling blood glucose levels, experience frequent episodes of severe hypoglycemia, or suffer from what is known as "hypoglycemia unawareness," a dangerous condition where the patient cannot recognize the symptoms of low blood sugar. These benefits—such as reducing the need for external insulin—must be weighed against the risks resulting from immunosuppressive medications [1], [2].

These procedures remain part of specific treatment options that require ongoing medical follow-up. For more details about this procedure, you can read our article on pancreatic islet cell transplantation for patients with Type 1 diabetes (Arabic). It should be noted that any decision regarding surgery must be made through specialist consultation to evaluate the individual's health status, as outcomes may vary from person to person, and these surgeries are not a definitive cure in themselves, but rather a treatment aimed at improving quality of life and glucose control.

Medical references

• Pancreatic Islet Transplantation
• Islet Cell Transplantation